Future of Healthy Longevity

Speaker 1

I’m excited to announce our second keynote speaker. Elizabeth Parrish is CEO of BioViva, a biotech corporation targeting cellular aging. that develops therapies to regenerate muscle and tissue. BioViva believes everyone deserves access to these life saving therapies. Elizabeth is a humanitarian entrepreneur, innovator, and a leading voice for genetic cures. As a strong proponent of progress in education for the advancement of regenerative medicine modalities, She serves as a motivational speaker to the public at large for the life sciences. She’s actively involved in international educational media outreach and is a founding member of the International Longevity Alliance. She’s an affiliated member of the Complex Biological Systems Alliance, which is a unique platform for Mensa based, highly gifted persons who advance scientific discourse and discovery. The mission of the CBSA is to further scientific understanding of biological complexity and the nature and origins of human disease. She is the founder of BioTrove Investments, LLC, and the BioTrove Podcasts, which is committed to offering a meaningful way for people to learn about and fund research in regenerative medicine. Please join me in welcoming Elizabeth Parrish.

Elizabeth Parrish

Thank you. That was very long. I’ll never do that to a person again. It’s not necessary.

Elizabeth Parrish

So it’s a pleasure to be here, and it’s a very beautiful part of the country. I’ve got to say, I looked out the window this morning. I came in when it was dark, and I looked out this morning, and I was. Struck by awe. I think that if I had a religion, it would be that of nature. I am very humble to the universe that I was born into.

Elizabeth Parrish

So when I Was asked to speak here. Lincoln asked me to talk a little bit about maybe faith and spirituality. I wasn’t raised religious, so I don’t have probably a lot of thoughts. I’ve learned a lot since I’ve been here. But I can say that if we put our faith in one place, we should put it in ourselves, because we can hold ourselves to getting a job done. And we can’t really hold anyone else to do that.

Elizabeth Parrish

When I was in college, I asked my chemistry teacher if he believed in God. And he said that science is actually the proof of God. Because, why would a man or a woman work their entire lives for something that they may never see the fruition of? And I thought that that was really beautiful. And I think that that can play into everything that we think.

Elizabeth Parrish

But the thing is, is that we’ve been handed many. Tools. We’ve either found them or been given them, and it doesn’t matter where you think they came from. If we don’t use them, they’re useless. So it’s important to place our faith in places that make us actually actionable. And so by placing faith in yourself, You know that you can get up and do the job. Please don’t wait for someone else to do it.

Elizabeth Parrish

I’m a perfect example of that because I’m the least likely person to be standing here. I got my education, didn’t quite finish it because I had my second child. I was a stay-at-home mom working part-time for my husband’s companies, and my son was stricken with type 1 diabetes. I ended up in the hospital, and I saw that many kids like him were suffering from chronic diseases, and many kids were dying. And yet, I had read that many cures for diseases had already come to fruition for animals in the research model, but these were not coming to humans.

Elizabeth Parrish

Okay? And so I asked around the hospital, and they said, well, it’s very unethical. Bioethics to use experimental medicine in humans. But I think it’s unethical to let people die. So I left the hospital and I went on a search to find my way of what I could do to make a change here to help kids that had diseases. Find cures.

Elizabeth Parrish

And I ended up at a CENS conference, which is Aubrey de Grey’s group. And I think that he spoke at one of your events a couple years ago. And I learned about biological aging. And I had a big epiphany. The genetic cures for biological aging are actually similar to the cures that will help treat a myriad of childhood diseases.

Elizabeth Parrish

Every day, we lose over 100,000 people to biological aging. Each one of these persons could have stepped up and been a test subject to bring cures to the world, not only for themselves, but for the community and our children as a whole.

Elizabeth Parrish

So I started a company called BioViva in 2015 with the ambition to get. Genetic cures out to humans and give them access to these treatments. A lot of governments were very interested in what we were doing. A lot of regulators were interested in what we were doing, but they really didn’t know how to move us forward. Being in a pickle after two years of searching for ways to treat humans, this year we actually started a partnership with a company called Integrative Health Systems that will actually help us start treating humans right now. Now. And this is really fantastic partnership because now we can legally get access to people, and BioVivo will run their data. So, BioViva is turning into a bioinformatics company that will run the data of what happens when we treat humans with gene therapies that actually treat the core root of biological aging.

Elizabeth Parrish

So, with no further ado. So, global disease burden. Why would we be looking at biological aging? Biological aging, cellular degeneration, is the root cause of what causes the diseases that we die of. So if you think of biological aging as a disease, Which we do, you’ll actually see that it’s the accumulation of damage as we age that leads to the symptoms that we die from. So that would be anything from cancer to heart disease to kidney failure to COPD.

Elizabeth Parrish

So, how have things changed over the years? How have we already become transhumanists? So, in the 1900s, this was how we died. Predominantly, we died of infectious disease. Okay, so when during this This time people would die around the age of 30 to 45 and they would die vastly of infectious disease. And if you look on the left side of the graph, you’ll see many diseases missing because they were basically unknown.

Elizabeth Parrish

But by 2010, we see that only 3% of the population is dying of infectious disease. even though it makes headlines, okay? And that’s because of antibiotics and immunizations. It vastly changed how humans lived and how long they lived.

Elizabeth Parrish

So when we look at the argument of is biological aging actually driving disease, you can actually see it on this graph. We see cancer rise significantly after 40. We see heart disease again on the rise after 40. As a matter of fact, the death curve for most people in the world starts around the age of 45 right now in industrialized countries. Diabetes type 2. This is not type 1, but it vastly rises as we age, as well as Alzheimer’s.

Elizabeth Parrish

So if we question what’s happening at the cellular level and what is actually making these diseases rise, we can actually get to the root cause of why there is so much interest in longevity today. Now companies in science has turned its eyes towards cellular degeneration, and now we’re looking at treatments that will actually affect What it will soon be by 2050, 2 billion people of the population.

Elizabeth Parrish

So by 2050, the people over the age of 65 will be 2 billion. This is a huge disease burden because, in the world right now, in some places, we only have one payer to every Five or six persons that need health care sitting on top of their head. We don’t have enough people entering the workforce. To actually deal with this burden. And this graph actually demonstrates that.

Elizabeth Parrish

So by the year 2020, we have more people over the age of 65 than under the age of 5. And this is actually a global number. So this accounts for every place on the planet. Planet. Some countries have far surpassed that. I was just in Hong Kong a few days ago, and it’s the longest-lived population, and they have very, very few children. And we see this all around the world as lifespan increases. People choose to have fewer and fewer children. But this creates a huge disease burden and a huge economic disaster on the planet.

Elizabeth Parrish

So here is aging in the middle, and here are all of the problems that are associated with aging. We call these diseases trillion-dollar problems. So the global annual cost of dementia right now is nearly a trillion dollars. Cardiovascular disease, also nearly a trillion dollars. Cancer is actually already surpassed a trillion dollars. This is a little bit old. And diagnosis of diabetes is also in the nearly trillion dollars. So, our company is looking at therapeutics that will actually combat this cellular degeneration. Causing these problems.

Elizabeth Parrish

But is it just a matter of how much money we spend on resources for humans? This graph will show you that, in fact, it’s not. The U. S. spends the most in health care right now of any other country. And has the lowest lifespan of all the industrialized countries, just coming in slightly above Turkey. So we need to really consider how we’ve been doing business and what we think is safe drugs.

Elizabeth Parrish

The U. S. is 5% of the world’s population. We take 75% of all the prescription medicine, and we have the shortest lifespans. So when the regulators tell me that we need safe drugs, I absolutely agree with them, but I don’t believe that they’ve passed any.

Elizabeth Parrish

Health is what we see on the left side. This is what we want to emulate. We want to be rambunctious. We want to be out there with nature, especially if you’re me. We want to be part of society, we want to be building outwards into communities

Elizabeth Parrish

What we see on the right side here is what happens as we age, and there’s a phenomena called mortality priming. These people tend to turn inwards. They share less of their resources. And actually, it’s not dependent on age. If you’re diagnosed with an end-stage disease in your 20s, you have the same mortality priming that happens with age. We see communities shutting down as they’re aging. And so, as you look at the whole world’s global population and the potential catastrophe, not only on the economic burden, but people turning inwards, this is definitely a problem that we need to solve. Now.

Elizabeth Parrish

So, prevention and cures. This is what drug discovery looks like today. This is, we have 5,000 to 10,000 compounds that start to go through trials and only a small, small percentage, depending on who you talk to, anywhere from 3 to 8 percent, will actually become viable drugs. So, what is going wrong? There are many things wrong. We have problems with academic papers that can’t be reproduced. We have problems with animal models that are not close enough aligned to the human body. Our company’s goal is to solve this problem, to be the platform that drug companies come to before they try to raise what is now over a billion dollars to take a drug through clinical trials.

Elizabeth Parrish

If you wonder why investors don’t Want to get involved in biotechnology, this is the reason. They tend to get in and get out really quickly before they head into phase three. Okay, because they want to take their profits. But health should not be a profit-based organization. This should be for everyone, and this should not be based in the needs. For large sums of money. Thanks.

Elizabeth Parrish

So, our company’s platform is to take promising drugs, especially in the gene and cell and regenerative therapy forum. And to actually give these companies access to 10 to 20 patients who will buy consensual use and help pay for the therapies as well, come and try the therapies, so that when a drug company Wants to bring their drug to the market, they can actually slap down the data of what happens in 10 or 20 people and show whether their drug works or not. Imagine a world where a drug company can go back to the drawing board and fix the problems with their drugs before they milk the system for a billion dollars. Imagine a world where we actually know where the drug works and how succinctly it works, and not. By not allowing the drug company to determine its own endpoints, but looking at them in a myriad of different data points to assess where the drug is and is not working.

Elizabeth Parrish

This is what today’s drug development also looks like in other graphs. So we see as the cost to get a drug through the FDA has risen, drug development has gone down dismally. We have less and less innovation. Coming through. And over here on the right, we have actual efficacy rates, which are also dismal. So in cancer, it’s about 25% efficacy. Right now, with gene therapies and immunotherapy, we actually see. A rise in the potential of having more of the population treated by safe drugs than ever before, which is very exciting.

Elizabeth Parrish

Again, the power of the gene. If you look at all the other numbers, I mean, you can see that many, many people are taking drugs that are not effective for them. So they’re not working. So, what they’re doing is getting a myriad of side effects without the benefits.

Elizabeth Parrish

And our hope with gene therapy is that when we succinctly look at the gene that we want to upregulate, we’re only upregulating the protein that gives you the benefit that we’re looking for. Therefore, the off-target side effects, everything’s a side effect. We’re looking for the positive ones, but the negative ones shouldn’t be so relevant. Or prevalent, I should say. They’re definitely relevant.

Elizabeth Parrish

So this is what drug development has historically looked like up until now. On the left side of the chart, you see therapeutic interventions that are trying to target. Diseases specifically and succinctly towards essentially treating symptoms of biological aging. So they’re going directly after neurodegeneration and atherosclerosis and cancer, but in fact, what we need to work towards is. What’s happening on the right side of this graph? Therapeutic interventions, when they look directly at biological aging, can knock all of these diseases off the board, I would say, except cancer, quite succinctly.

Elizabeth Parrish

Cancer We have some problems with that because much of it is still environmental, and so until we find genes that Help to keep genomic stability as sound as possible, which I think that we can do, we will still be plagued with cancer. But when we look at biological aging succinctly, we can actually knock each one of These processes or symptoms of aging off at one time.

Elizabeth Parrish

So, what is the power of treating biological aging? Today, if we looked at the yellow bar is an average woman living to 81 years, okay? If we had a cure for cancer today, she would only live two more years. That’s significant, but it’s really not incredible. And a cure for heart disease would only add four years to her life. Curing cancer, heart disease, and stroke and diabetes would add 16, which is significant. Now we’re talking. But if we just slowed aging, It would add 33 healthy, productive years to her life, keeping her in the workforce longer, keeping her from being debilitated, keeping you from having to pay for her health care.

Elizabeth Parrish

This is a really nice video. This is a family in Oregon. And essentially, every year for I think 40 years, they took a picture together. And what’s so beautiful is this, they’re beautiful in the beginning and they’re beautiful in the end, but during these photos, you can see what aging does to our bodies. You can see what happens on the outside. It actually is a remarkable disease that is very visual. It doesn’t hide itself. And what’s happening on the outside of their bodies is happening on the inside of their bodies too. David Kelly, I’m not sure where he’s at right now, but he had a conference that I spoke at, and we showed what the inside of an 85-year-old brain looked like compared to a 27-year-old. And this was an 85-year-old who didn’t have dementia, and it was really quite devastating. I wish I had that slide. Again, beautiful women, but they’re definitely going through the process of aging and heading towards their own demise.

Elizabeth Parrish

This is what’s happening inside ourselves. These are the 10 hallmarks that we know of right now that is driving biological aging. And knowing these hallmarks is the beginning of the battle. This gives us a potential to actually intervene. So, you can see that there are things that are happening on the outside of the cell, and there are also things that are happening on the inside of the cell. So, we have things like cellular exhaustion, loss of proteostasis. We have cellular senescence, and a lot of people have been hearing about senescence lately because one company has raised a lot of money who is going after arthritis, and they’re using it with us using a senescent cell-killing gene therapy. extracellular matrix, dysfunction, and so on and so on, including telomere attrition and dysregulation and nutrient sensing. So by knowing these ten hallmarks, we can actually start to Develop therapies that reverse the issue. And what we really are looking for is a cell that regenerates and restores as fast as it degrades.

Elizabeth Parrish

So the Methuselahs. The Methuselahs are organisms that their life has been extended significantly through gene modulation. And these are them. So you can see that worms, their lives have been extended by now, actually 11 times. Flies by 4, killifish by 5, and mice now, I believe, by 5 times. Times.

Elizabeth Parrish

This is actually fantastic information. It shows us the power of gene modulation, but actually, in nature, we can see a lot more interesting things that we may want to emulate. For instance, we can look at animals like mice, who don’t live. Live very long. And then a very close cousin called the naked mole rat who lives 35 years. So the mice live around two to three years, the naked mole rat. Lives about thirty-five years, and the difference is in their genes. The Bohelhead well lives to about 250 years. Again, the difference is in the genes. So now what we’re doing is searching and looking at organisms that don’t get cancer. That don’t suffer from diseases of aging and that live an extremely long period of time. But the Methuselahs help us a lot because it shows us that gene modulation can, in fact, lead to longer lifespans.

Elizabeth Parrish

So now it’s time to do it in humans. But how do we do it in humans and determine how long a human would live? Because a human can live up to 80 years. The reason we do research in mice is because they live a very short period of time, and so it’s very Evident when we’ve extended their lifespan.

Elizabeth Parrish

We can look at predictive markers of biological aging. So here in the middle, the red line that is curving down, you see the death curve, and here you can see people. At their different aging trajectories. So, not everybody biologically ages at the same rate. Some of us are biologically older than our peers of the same age, which is very interesting. And so, what we need to do is basically. Science the crap out of this. We need to understand and actually build predict

Elizabeth Parrish

Biomarkers of biological aging, and I’m here to tell you that unfortunately they do not exist at this time. In our platform, we’d like to run new companies. Biomarkers of aging to see how accurate they are over time with our products. But right now, what we’re doing is looking at about 7,000 data points in patients to analyze how well they’re doing.

Elizabeth Parrish

When you go to the doctor and you’ You’re 75, and the doctor says, Oh, you’re looking healthy. Let me pat you on the back. You’re not healthy at 75. It’s actually a physical impossibility today. So, what we need to do is have a better examination on what health actually is, and we need to gauge against that.

Elizabeth Parrish

Some of the things that we’ve talked about in the past. Are things like telomere length? Would telomere length tell us how old a person is biologically? Well, actually, it doesn’t because what happens is telomeres get short. It can be a predictive measure of how soon you might get a disease, but actually, telomeres can stay. Short for quite a significant amount of time. So, as science is progressing and as we’re using the tools we’re given or finding, however you want to see it, we’re able to use those tools to really drill down on what we’re looking. At when we talk about biological aging.

Elizabeth Parrish

So, the requirements for a proper biomarker should be predictive physiological, cognitive, and physical function of chronical age. They should predict the years of remaining. Good function. That is the thing that we have a difficulty in doing right now. Minimally invasive and accessible to all people. Again, I don’t believe that health should cost money. I think that we need to realize that by having healthy people, we actually save an enormous amount of money, therefore, pocketing many resources. Must be more than just decreased risk factors and should represent individuals’ overall health.

Elizabeth Parrish

So, the three types of markers that we look at right now are methylation profile, proteome, and telomere length as far as the molecular. Clinical is the VO2MAX and the CPACS, and physiological is the MRI imaging and visceral fat ratio. And these actually are pretty accurate for health. But again, from the standpoint of health, it is really hard to Have a proper marker of your biological age. We can just say whether or not you’re healthy in one part of your body, but maybe not all of it.

Elizabeth Parrish

So what we’re looking at as a company now is looking at omics, omics, omics. How many omics can we get on a person? And then you’re thinking that maybe we might have the problem solved, except for vastly these omics are still not understood. Silence. But does that mean that we shouldn’t actually gather them? No, because they’re being better and better understood over time and can actually help us build a profile of health that will actually whistle. Future development.

Elizabeth Parrish

And the reason that we can do this is because the cost of genetic sequencing has gone down significantly. And remember, you can not only get your genome sequence, but you can actually look at your microbiome and a mirror. Of other fantastic areas of your health these days. And as our understanding of the genome increases, our ability to alter And edit, the genome increases with it. So, with understanding, we proceed even faster.

Elizabeth Parrish

So bioinformatics is what the company is working on now. We’re working on fast tracking the development of drugs so that they benefit you even sooner. And some of the other markers that we would look at are these ones, epigenetic profile mutations. NAD is really popular these days, especially when we’re dealing with Vascularization of the body, blood analysis, telomere length, senescent markers, DNA repair activity, and wound healing.

Elizabeth Parrish

And this actually is really interesting because we certainly don’t want to cut you and that. Then have you tried to heal? One of the unique ideas that we’re working with now is how to take cells from a patient and accelerate the aging in those cells to glean. What diseases that you might die of in the future? It’s kind of exciting and it’s very interesting process. And what this does is gives us the ability to do real personalized medicine. So, right now,

Elizabeth Parrish

The gene therapies that BioViva is bringing through the platform are genes that we can all benefit from. But as we run more into the future, we know that some of us have genes that are beneficial to longer lives. We know some of our families live at Extremely long, mine certainly doesn’t. And so we will want to have precision medicine that helps each patient actually achieve their maximum outcome.

Elizabeth Parrish

So that starts with Diagnostics and prognostics. And again, this is the data points that I can’t overstate more. These data points are very, very important. Personalized experimentation. Would be the cell-type cultures to increase the aging in the cells and to see what your risk factors may be. And then, of course, personalized treatment. And we’re not actually doing these in orders because we don’t believe that we can wait to have everything.

Elizabeth Parrish

In line, that human data is the most important thing, and that we must collect that human data to get there. I was talking to Parker earlier, and we talked about, yeah, you’re smiling, we talked about the mountain that we’re standing on now. And the advancements that we have today, and the mountain that we want to get to, and that actually nobody seems to want to travel through the valley of potential death to get there. But in fact, we don’t get there unless we travel through that valley. Okay, we have to be actionable. We have to realize that right now we have 100% Risk of death. And in order to get to the other side, the upgraded human, we’re all going to have to take part in the experimentation.

Elizabeth Parrish

We’re all going to need to be a proponent and an active Faith-driven, even if it’s an interfaith-driven person, in order to get this data. Today, Integrative Health Systems, the company that we’re working with, has plenty of people that are in high need of treatments. And that’s fantastic because that will get. Give us some amount of data. But we would like to move those gene therapies back into preventative medicine because that’s where the real cost savings is. When we use them as preventative medicine so that you don’t get sick to begin with, we can see the true power of the therapeutic.

Elizabeth Parrish

So today there’s 425 gene therapies in trial, and that’s pretty fantastic. And there’s 523 cell therapies that are in trial. And this is really good news for everyone, but even being in trial does not mean that these therapies will get to you in an expedited manner. So you really need to push your legislators to open up for experimental medicine so that all people can have access to them. And tissue engineering lies somewhere in between the cell and gene therapies. We generally use both.

Elizabeth Parrish

So, how will BioViva actually get data on humans that is meaningful and accurate? And how will we help patients? Well, we can help them with adaptive clinical trials by actually ensuring that the right patients are getting access to the right. Therapeutic. By doing this, we actually minimize a lot of the buzz and the noise and the garbage in the system, ensuring that our outcomes are as relevant as possible. Remember, we are not here to pass. Any particular drug, we’re just here to see if they work or not. So, the ideal therapeutic requirements would be, you know, safety data in animals, even though we know that.

Elizabeth Parrish

It is sometimes weak at best. But having some sort of toxicology data is pretty important to moving therapeutics forward. And having affirmed efficacy in humans is even better, and that’s where we step in: to actually give humans the autonomous right to access therapeutics. And we do believe that it’s your human right to do this, that no government should pull over your head that you. You do not have access to do anything you want with your body.

Elizabeth Parrish

We would like to modulate multiple aging biomarkers at once. Those hallmarks of aging that I showed you, if we can hit more than one, we would be thrilled. If we can just hit one, that would be fine because we’re actually looking for the combinatorial therapy of the future that you will take. A preventative effect, we’ve already talked about this. We’d like to build these. Type of therapeutics into preventative medicine, very similar to immunizations. And actually, gene therapy is very similar to an immunization. and a regenerative effect.

Elizabeth Parrish

Of course, slowing aging would be a multi-trillion dollar market, clearly. But reversing biological aging is really the goal, creating Gene therapies that regenerate the cell faster than it actually degrades. And we have good evidence that we can do that with what we have now. And over time, these therapies will get better and better.

Elizabeth Parrish

Okay, so diagnostics, prognostics, personalized experimentation, personalized therapies. And equal restorative medicine. And I won’t bore you with the slide because we have limited time. And if you’d like to see it, anyone is welcome to have access to our slides. But this is essentially a recipe. For success. This is a recipe for how we actually get drugs through and through a human trial and actually have better data than we would through a regulatory body. Because remember, when you go through a regulatory body, many of the companies can actually hide their data.

Elizabeth Parrish

So who am I and why am I telling you that you should take a gene therapy? In 2015, to launch the company, I took two of the gene therapies that showed the most promise for humanity. And I’m happy to say that we have proved safety, which is wonderful, and we are showing some amount of efficacy as well. One of the gene therapies I took was a telomere lengthening gene therapy. It holds great promise. It’s the only gene therapy that’s reversed biological aging in animal models. It actually tackles many of the hallmarks of aging.

Elizabeth Parrish

So why do I not look like I’m 20? Because biology is a very, very difficult thing to work with. Okay? With some gene therapies, we only need to target a few cells in the body, and we have what’s called a shared protein, a protein that goes out into the blood and is shared with the whole body. And that would be the one on the right, the myostatin inhibitor. This one increases your muscle mass, and as a matter of fact, this has already been through safety and efficacy in the United States. That was the second gene therapy I took.

Elizabeth Parrish

But the telomerase-inducing gene therapy has to be in every cell. Shared outside your cells. And we do not know how many of the cells in my body we targeted, but we can glean from the effects of the testing that we targeted maybe around 20 or 30 percent.

Elizabeth Parrish

So, the data, what was the data? We definitely saw lengthening in the telomeres in the T lymphocytes. And we actually, in this case, used the same lab and the same test. So, we did that to. Actually, shorten the level of inaccuracy in their own testing. We use the same lab. And we saw definitely increased muscle mass and decreased intermuscular fat, which is fantastic.

Elizabeth Parrish

We did an MRI on my entire body, and we have no signs of cancer. We’ve done many cancer. Tests and I’m they essentially come out you’re at a high mid or low risk and I’m at a low risk for all of them

Elizabeth Parrish

Let’s see, we saw a six-fold reduction in C-reactive proteins, which are a sign of inflammation. And so if you have inflammation, if my C-reactive proteins would be high, that would Kick off things like cancer. We’d have some indication that I might have cancer or some amount of immuno problems going on in my body. We don’t see any. As a matter of fact, they’re extremely low because they were normal when we started. Again, this was just a couple of the cancer tests of things that run in my family that had very low risk.

Elizabeth Parrish

twenty five percent reduction in blood glucose levels. So when we increase muscle mass, the great thing about that is not only do you feel stronger and more independent as you age, but it actually fights what we call metabolic Disorder. So metabolic disorder is essentially things like type 2 diabetes. You increase the muscle mass, you decrease the intramuscular and intraorgan fats, and you have a body that actually Is more sensitive to insulin. And that’s fantastic. And my HBA1Cs, which is a long-term indication of how my blood sugar is doing, is extremely good.

Elizabeth Parrish

For my age group, we also saw a reduction in triglyceride levels of 50%, and that means better heart health. And the thing is, is that these markers have actually continuously stayed low. That is a really happy finding. I think that actually with one scientist in California who was running some of my data, He ran up and gave me a big hug when he saw my first biomarker change. And it was, I don’t think I’ll ever forget it. And I said, why are you hugging me? And he said, your blood glucose levels are down, your metabolism’s better. This is the first change we’re seeing from the therapy. So that was really exciting.

Elizabeth Parrish

So as far as the damage that could have been done with the current technology, we have not seen liver damage, which was one fear that we would see at the high level of viral vectors that I took, and no sign of kidney damage or cerebrovascular changes.

Elizabeth Parrish

So, our ultimate goal is health. Okay, I think that we can go a lot farther than that. I think that we can start looking at other species like technology. Have you ever gone snorkeling and saw a squid change colors in front of you and do fancy things? I think that as humans, we have the potential to be. Limitless, but I have to say that health is the first place that we need to start. And before we start the debate on extreme lifespans, we have to prove that we can do it, okay? So we have to find these drugs, and we are the platform for. Seeking them out.

Elizabeth Parrish

The World Health Organization defines health as this: health is a state of complete physical, mental, and social well-being, and not merely the absence of disease or infirmity. Who sits under that definition today? We would like to hold the World Health Organization responsible for this definition and help the world actually achieve this. So, thank you for listening.

Elizabeth Parrish

Have any questions, I can where do you get some? Well, you actually can contact a company called integrativehealth systems. com and I wouldn’t You should probably come through BioViva and email BioViva. We’re at bioviva-science. com because there’s a lot of integrative health system companies, companies with that sort of title, and we can give you the direct link to them.

Speaker 3

How many persons have used the therapy since field? Or maybe you could just clarify whether anybody has it there.

Elizabeth Parrish

Yeah, so all right now we’re opening up integrative health systems, so all of the patients before that are all anonymous, and so I can’t disclose any of that information, but we’re hoping to have the data that we We can share. These patients will all be anonymous as well, but they all have to agree to sharing their data.

Speaker 3

So others can.

Elizabeth Parrish

Yeah, so we have some. Well, I can’t say that because I might be embraced in some things, but I do say that we have some indications of. Definite safety across the board with at least these two gene therapies, and then we’ll ask the same for other companies or obtain it for them.

Speaker 4

I was wondering if you had looked at nutritionomics, which is a potential pathway for achieving some of your objectives, namely gene therapy. And second, in gene, Are you saying that you can take like a phaline and change it into a methionine and a single liquid type polymorphism? I’m thinking of especially the methylation profiles.

Elizabeth Parrish

For the first question, you’ve got to talk to our bioinformatics people. And if you have a good suggestion, we’re always open to suggestions. I don’t know if it’s something they’re looking at or not. So that’s a good question. CRISPR actually is giving us the first gleam that we can actually. Change genes within the genome and not only cut and edit them, but actually methylate or turn off or turn on genes that are already there succinctly. And that’s what we’re really excited about. When I talk about gene modulation in model organisms, these are essentially turning genes on or off. The future, Of actual genomic therapies will be modulating the genes in the true sense of having a dimmer switch. We don’t have that right now. We have on and off, and that’s it.

Speaker 6

I’m a type 1 diabetic, so it’s not really an age-related disease. But you mentioned that you started it in Eastern, if you were interested in working on that. What are your son on that?

Elizabeth Parrish

Right, so my son has type 1. Diabetes, and that’s what threw me into this, and that’s what encouraged me to take this test. And so one I think that that’s a really important thing to touch on for two reasons. Number one, to answer your question, there are a lot of companies doing really great work in type 1 diabetes. They’re not only looking at it genomically, but they’re looking at some fixes and tests. We can get to the point where we can actually do immunotherapies that will stop the immune system from attacking the pancreas. And yeah, I’m really, really excited about this.

Elizabeth Parrish

As a matter of fact, I brought my purse up here. Usually I have my son’s Dexcom, which, so, you know, it reads his blood sugar in real time, but right now he’s Playing soccer, so he has no data. So I went ahead and put it in my purse, but usually I have it out during my whole talk so that I can monitor him. So I commend you. Everyone says, you know, it’s a manageable disease, and you know as well as I know, it becomes a part. Part of your life, and it becomes somewhat normalized, but I don’t think that we should ever acknowledge it as a normal part of existence. So I’m looking forward to the eradication of it.

Elizabeth Parrish

We have looked at a couple of gene therapies, one for the gut lining. That can actually create, yeah, it can make the gut lining cells create insulin when they sense sugar. But again, right now, we’re just for the first time this year putting money into research. Development with Rutgers University in order to create a gene delivery method rather than a specific gene therapy. So, what we want the ability to do is actually deliver any gene for any disease at. Needed for patients. But as far as the type 1, you know, a lot of people think, well, this is a treatable disease, and what are the big complaints? Well, chronic disease is actually a very plaguing. State of being. And, you know, type one is something that you’re managing all day long. You’re high, you’re low, you finally have some breakthrough and you have somewhat normal blood sugar for eight hours, and then you’re high and low. You’re all over the place. And it’s a huge burden for these people. But of course, we’re here for all diseases and not just one. Sure.

Elizabeth Parrish

Can I put an idea out there? So it’s a little crazy. Oh, yeah.

Speaker 7

It’s okay. Um so I don’t know if you heard of Dr. Henry Daniels’ work where he uh Takes in plants, lettuces, and put them all so that they can release into the body. When he takes the pro-insulin gene, it’s consumed, the cellulose protects the pro-inulin He has a cholera coconut, so the body is older, it’s going to be a test kines. And he says that it actually trains the immune system not to attack the beta cells when you do that.

Elizabeth Parrish

Yeah, I haven’t heard about it, but I have a whole folder and I keep up on all the technology coming through. I’m excited about the under-the-skin implants, and I understand that just in the next few months, we’ll have. Fast-acting insulin that acts within five minutes, but I really still think that that’s a poor step in the direction of a cure.

Speaker 8

What kinds of gains I suppose we call the goals is IOEVO or maybe even precision medicine is a field looking at in terms of the extension of, let’s say, an average of one year life extension or longevity. What might that cost? Project out in.

Elizabeth Parrish

So, as a therapeutic, what would it cost? Well, we’re hoping by the time, well, there are many things that right now that we’re using, just like washing your hands and basic sanitary practices, that extend. Our lifespan today, but if we had a gene therapy that could extend your lifespan by a few years. I’d hate to put a value on things, but I can tell you that right now gene therapy is massively expensive. So when we do our gene therapies, it costs tens of thousands to hundreds of thousands of dollars, upwards of a million, depending. On what a person wants to take into their body. And that’s just having the gene therapy manufactured. So, one of the areas where we’re putting money now is into manufacturing to see if we can cut the cost by about 60%. But when we have the combinatorial therapy that actually extends life significantly and keeps people healthy and active, my hope is that it is very, very low cost and accessible by everyone. And I think that we have a lot of reasons for that to be because even the people who could afford it now don’t want to pay for the people who can’t afford it later. So I think those things will work themselves out. But right now, it’s pretty cost prohibitive.

Speaker 9

When you you express the aspiration to make it affordable for everyone, I wonder if um how far that aspiration goes. You know, I’m I’m thinking of persons that currently live in sub-Saharan Africa. Is that so far away that it’s not even worth thinking about at this point? Or are you thinking that the cost of these sources can come down fast enough that that’s reasonable to think of?

Elizabeth Parrish

I think that when we think about advances, we should think about the technology for everyone. We should think about how that increases society’s ability to actually overcome adversity. So for instance, the first industrialized Industrialized revolution, somebody helped me with this word, happened because of lifespan. So, as soon as people live long enough to get trained and then be an active part of the workforce for a longer period of time, this is when we’ve seen the big boom. In industrialization. And this is also when we see them in countries that are burgeoning.

Elizabeth Parrish

So as soon as a country’s lifespan gets past a certain Age, we actually see that OECD countries go in and they start buying up workforce. And so we saw this with China and India and other places in the world that we reach into as long as, as soon as the workforce Force lives a significant period of time where you can actually train them and get actionable work out of them. Now, with our company, of course, we would like to work into stronger, faster, better, smarter humans. You know, when people talk about AI, I would like a human brain that keeps up with it. And the only way that we can do that, first we’re will be vastly surpassed, but the only way we can do that is with genetically altering machines that are biological that integrate with us.

Elizabeth Parrish

So, somebody was saying early that a friend of theirs, you know, free. Out when they lost their phone because it really has become an extension of our mind. It’s like losing your brain. It’s like, oh my gosh, where did it go? And we’re all panicking. Integrating these technologies will be the next step after we solve these. These more what would be considered basic problems, but what right now are huge problems for society.

Speaker 10

Thank you, Work. We’re out of time right now for questions.